| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 58.77 | 5.9% | 57.0% |
| Total Income | 58.77 | 5.9% | 57.0% |
| Expenditure | 54.32 | 12.3% | 8.8% |
| PBT | 1.16 | 364.0% | 105.8% |
| Net Profit | 0.54 | 116.0% | 102.7% |
| OPM | 7.57% | 14.98pp | 40.98pp |
| NPM | 0.92% | 0.52pp | 54.46pp |
| EPS | 0.00 | 100.0% |
Akebia Therapeutics Announces Q3 2025 Financial Results
04 May 2026 · 4 May, 7:31 am
Summary
Akebia Therapeutics, Inc. issued a press release on November 10, 2025, announcing its financial results for the third quarter ended September 30, 2025. The press release, which includes financial results and recent business highlights, is furnished as Exhibit 99.1 to the Current Report on Form 8-K. The information contained within the report is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1
Akebia Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2025.
- 2
The press release contains information about the company's financial results and recent business highlights for Q3 2025.
- 3
The information is furnished as Exhibit 99.1 to the Current Report on Form 8-K.
- 4
The press release is dated November 10, 2025.
Informational and educational content only. Not investment advice.